Skip to main content

Table 2 Associations between genetic risk scores and overall RA risk, as well as ACPA-positive and ACPA-negative RA risk

From: A genetic risk score composed of rheumatoid arthritis risk alleles, HLA-DRB1 haplotypes, and response to TNFi therapy – results from a Swedish cohort study

GRS Overall RA ACPA-positive RA ACPA-negative RA
GRS76SNP
 Linear 2.03 (1.85–2.23) 2.44 (2.19–2.72) 1.21 (1.03–1.44)
 Q1 Reference Reference Reference
 Q2 vs Q1 1.40 (1.02–1.93) 1.57 (1.04–2.38) 1.25 (0.77–2.05)
 Q3 vs Q1 2.39 (1.78–3.22) 3.43 (2.36–5.00) 1.33 (0.81–2.16)
 Q4 vs Q1 4.99 (3.77–6.61) 8.01 (5.60–11.45) 1.49 (0.92–2.42)
GRSHaplotype
 Linear 2.13 (1.94–2.34) 2.57 (2.30–2.87) 1.19 (1.00–1.42)
 Q1 Reference Reference Reference
 Q2 vs Q1 1.68 (1.21–2.34) 2.70 (1.69–4.33) 1.19 (0.74–1.91)
 Q3 vs Q1 3.64 (2.72–4.88) 8.11 (5.34–12.31) 1.06 (0.65–1.71)
 Q4 vs Q1 7.08 (5.24–9.57) 16.11 (10.51–24.69) 1.47 (0.89–2.41)
  1. Data presented as odds ratio (95% confidence interval)
  2. ACPA anti-citrullinated protein/peptide antibodies, GRS genetic risk score, RA rheumatoid arthritis, Q, quartile